Chemogenetic locus coeruleus activation restores reversal learning in a rat model of Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Abstract
See Grinberg and Heinsen (doi:10.1093/brain/awx261) for a scientific commentary on this article. Clinical evidence suggests that aberrant tau accumulation in the locus coeruleus and noradrenergic dysfunction may be a critical early step in Alzheimer’s disease progression. Yet, an accurate preclinical model of these phenotypes that includes early pretangle tau accrual in the locus coeruleus, loss of locus coeruleus innervation and deficits locus coeruleus/norepinephrine modulated behaviours, does not exist, hampering the identification of underlying mechanisms and the development of locus coeruleus-based therapies. Here, a transgenic rat (TgF344-AD) expressing disease-causing mutant amyloid precursor protein (APPsw) and presenilin-1 (PS1ΔE9) was characterized for histological and behavioural signs of locus coeruleus dysfunction reminiscent of mild cognitive impairment/early Alzheimer’s disease. In TgF344-AD rats, hyperphosphorylated tau was detected in the locus coeruleus prior to accrual in the medial entorhinal cortex or hippocampus, and tau pathology in the locus coeruleus was negatively correlated with noradrenergic innervation in the medial entorhinal cortex. Likewise, TgF344-AD rats displayed progressive loss of hippocampal norepinephrine levels and locus coeruleus fibres in the medial entorhinal cortex and dentate gyrus, with no frank noradrenergic cell body loss. Cultured mouse locus coeruleus neurons expressing hyperphosphorylation-prone mutant human tau had shorter neurites than control neurons, but similar cell viability, suggesting a causal link between pretangle tau accrual and altered locus coeruleus fibre morphology. TgF344-AD rats had impaired reversal learning in the Morris water maze compared to their wild-type littermates, which was rescued by chemogenetic locus coeruleus activation via designer receptors exclusively activated by designer drugs (DREADDs). Our results indicate that TgF344-AD rats uniquely meet several key criteria for a suitable model of locus coeruleus pathology and dysfunction early in Alzheimer’s disease progression, and suggest that a substantial window of opportunity for locus coeruleus/ norepinephrine-based therapeutics exists.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The brain noradrenergic system is also critical for cognition and noradrengergic dysfunction is a critical early step in AD progression 249.”
From Mechanisms of synaptic transmission dysregulation in the prefrontal cortex: pathophysiological implications (2022) · cites this paper as [249]
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Aston-Jones, G., & Cohen, J. D. (2005) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.28.061604.135709 · Cited by 4,472
Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years
Braak, H., Thal, D. R., Ghebremedhin, E., & Del Tredici, K. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318232a379 · Cited by 2,194
The locus coeruleus and noradrenergic modulation of cognition
Sara, S. J. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2573 · Cited by 1,848
The efficiency of systematic sampling in stereology—reconsidered
GUNDERSEN, H. J. G., JENSEN, E. B. V., KIÊU, K., & NIELSEN, J. (1999) · Journal of Microscopy · doi:10.1046/j.1365-2818.1999.00457.x · Cited by 1,317
Augustinack, J. C., Schneider, A., Mandelkow, E.-M., & Hyman, B. T. (2002) · Acta Neuropathologica · doi:10.1007/s004010100423 · Cited by 998
The dentate gyrus: fundamental neuroanatomical organization (dentate gyrus for dummies)
Amaral, D. G., Scharfman, H. E., & Lavenex, P. (2007) · Progress in brain research · doi:10.1016/s0079-6123(07)63001-5 · Cited by 888
Al-Atrache, Z., Cader, A., & Appelt, D. M. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.06.894 · Cited by 765
Cited by
Items 201–229 of 229
Yin, C., Kindt, A. S. D., Harms, A. C., Hartman, R., Hankemeier, T., & de Lange, E. C. M. (2025) · Metabolomics · doi:10.1007/s11306-025-02350-z · Cited by 1
Garcia, M. L., Denton, A. R., Jackson, N. L., Scofield, M. D., & McMahon, L. L. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1690410
Xiao, W., Su, J., Gao, X., Yang, H., Weng, R., Ni, W., & Gu, Y. (2022) · Figshare · doi:10.6084/m9.figshare.19609530
Pahl, J., Prokopiou, P. C., Bueichekú, E., Schultz, A. P., Papp, K. V., Farrell, M. E., Rentz, D. M., Sperling, R. A., Johnson, K. A., & Jacobs, H. I. L. (2024) · Figshare · doi:10.6084/m9.figshare.26728021
de Ávila, C., Guguła, A., Trenk, A., Intorcia, A. J., Suazo, C., Nolz, J., Plamondon, J., Khatri, D., Tallant, L., Caron, A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26315492
Pahl, J., Prokopiou, P. C., Bueichekú, E., Schultz, A. P., Papp, K. V., Farrell, M. E., Rentz, D. M., Sperling, R. A., Johnson, K. A., & Jacobs, H. I. L. (2024) · Figshare · doi:10.6084/m9.figshare.26728024
van den Berg, M., Adhikari, M. H., Verschuuren, M., Pintelon, I., Vasilkovska, T., Audekerke, J. V., Missault, S., Heymans, L., Ponsaerts, P., Vos, W. H. D., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21311016
Liu, W., 李建宏, Yang, M., Ke, X., Dai, Y., Lin, H., Wang, S., Chen, L., & Tao, J. (2022) · Figshare · doi:10.6084/m9.figshare.19596201
de Ávila, C., Guguła, A., Trenk, A., Intorcia, A. J., Suazo, C., Nolz, J., Plamondon, J., Khatri, D., Tallant, L., Caron, A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26315692
Engels, N., Koops, E. A., Hsieh, S., Wiklund, E. E., Schultz, A. P., Riphagen, J. M., Prokopiou, P. C., Hanseeuw, B. J., Rentz, D. M., Sperling, R. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26054646
Liu, W., 李建宏, Yang, M., Ke, X., Dai, Y., Lin, H., Wang, S., Chen, L., & Tao, J. (2022) · Figshare · doi:10.6084/m9.figshare.19596204
Pahl, J., Prokopiou, P. C., Bueichekú, E., Schultz, A. P., Papp, K. V., Farrell, M. E., Rentz, D. M., Sperling, R. A., Johnson, K. A., & Jacobs, H. I. L. (2024) · Figshare · doi:10.6084/m9.figshare.25951912
Pahl, J., Prokopiou, P. C., Bueichekú, E., Schultz, A. P., Papp, K. V., Farrell, M. E., Rentz, D. M., Sperling, R. A., Johnson, K. A., & Jacobs, H. I. L. (2024) · Figshare · doi:10.6084/m9.figshare.26728027
Morrone, C. D., Lai, A. Y., Bishay, J., Hill, M. E., & McLaurin, J. (2022) · Figshare · doi:10.6084/m9.figshare.19695705
Xiao, W., Su, J., Gao, X., Yang, H., Weng, R., Ni, W., & Gu, Y. (2022) · Figshare · doi:10.6084/m9.figshare.19609521
Pahl, J., Prokopiou, P. C., Bueichekú, E., Schultz, A. P., Papp, K. V., Farrell, M. E., Rentz, D. M., Sperling, R. A., Johnson, K. A., & Jacobs, H. I. L. (2024) · Figshare · doi:10.6084/m9.figshare.25951779
Talwar, P., Mortazavi, N., Koshmanova, E., Muto, V., Gasparello, A., Degueldre, C., Berthomier, C., Collette, F., Bastin, C., Phillips, C. L. M., et al. (2025) · Annals of Neurology · doi:10.1002/ana.78112
“The sleep-based interventions could take the form of cognitive behavioral therapy, light therapy, LC stimulation, 46 or pharmacological approaches targeting dopamine or norepinephrine modulation 47 and would need to be tested in large scale interventional studies.”
Hernandez, N. M., Silva-Pérez, M. A., & Chin, J. (2026) · PLoS ONE · doi:10.1371/journal.pone.0340611 · Cited by 1
“Reductions in noradrenergic axon density and norepinephrine content have also been reported in APP rats and were accompanied by learning deficits that were rescued by chemogenetic stimulation of the LC [43].”
Beyond dopamine: Broader neuromodulatory contributions in sign- and goal-tracking
Datta, A., Datta, A., Collins, N., Grella, S. L., & Gheidi, A. (2026) · Psychopharmacology · doi:10.1007/s00213-026-07013-y
Rae, R. J., Alberhasky, J. M. H., Baillet, M., Bangasser, D. A., Belloy, M. E., Berry, A. S., Berteotti, C., Bow, H., Buckley, R. F., Caldwell, J. K., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71291 · Cited by 2
Leveraging Optogenetic fMRI for Understanding Disease Processes in Neurological Disorders
Kelberman, M. A., Anumba, N., Daley, L., Marriott, A., Pan, W.-J., Weinshenker, D., & Keilholz, S. D. (2026) · Neuromethods · doi:10.1007/978-1-0716-5178-0_16
Self-citationKoops, E. A., Giudicessi, A., Baena, A. Y., Martinez, L., Félix, N. A. B., Medrano, R., Dutta, J., Gonzalez, I., Álvarez, S., Aguillon, D. F., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71587
Levine, C. M., Caggiano, C., Anderson, T., Kelberman, M. A., Weinshenker, D., Lail, H. L., Wanders, D., Bangasser, D. A., Kanoski, S. E., & Parent, M. B. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-06014-4
Self-citationNext-generation chemogenetic inhibition using a brain-permeant non-prescription agent
Devenish, S. O., Patel, S. D., Ussingkær, L. V., Silva, L. F. A., Goff, O., Richardson, A., Mobbs, J. I., Venugopal, H., Thal, D. M., & Kullmann, D. M. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02865-4 · Cited by 1
Xing, S., Ren, P., Chen, Z., & Fu, Y. (2026) · Neuroscience · doi:10.1016/j.neuroscience.2026.07.063
Bhattacharya, A., Manjithaya, R. R., Chickabasaviah, Y. T., & Alladi, P. A. (2026) · Annals of Neurosciences · doi:10.1177/09727531261462296
“125 Several reports have alluded to the possibility of neuronal recompense within LC in AD in the form of enhanced expression of TH and NET in the perikarya, sprouting of dendrites and axons, enhanced turnover of cortical NE 36,126 and a higher level of galaninergic innervation on the remaining…”
Prokopiou, P. C., Egroo, M. V., Riphagen, J. M., Baillet, M., Ashton, N. J., Janelidze, S., Sperling, R. A., Johnson, K. A., Blennow, K., Hansson, O., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71703
“56,57 Additionally, reductions in cortical NE concentrations induced by LC lesions were associated withelevated astrocyte reactivity, 10 reducedADpathology clearance, 11 andcognition.”
Vreven, A., Chandler, D. J., Fan, W., Jordan, R., Krentzman, O. J., Lüthi, A., McCall, J. G., Sciolino, N. R., Tkaczynski, J., & Totah, N. K. B. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-24078-2.00010-3
Eassa, N. E., Perez, S. M., Yang, O. J., Boley, A. M., & Lodge, D. J. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6c00432
Metadata
- Authors
- Rorabaugh, J. M., Chalermpalanupap, T., Botz-Zapp, C. A., Fu, V. M., Lembeck, N. A., Cohen, R. M., & Weinshenker, D.
- Affiliations
- Emory University (US)
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-09-25
- Volume
- 140
- Issue
- 11
- Pages
- 3023-3038
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC5841201
- OpenAlex
- W2760256027
- Cited by
- 227
- References
- 72
- Citations by year
- 2026: 24 · 2025: 25 · 2024: 39 · 2023: 20 · 2022: 45 · 2021: 26 · 2020: 18 · 2019: 14 · 2018: 13 · 2017: 3
- FWCI
- 9.71
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Brain (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (AG0476670, NS007480)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- locus coeruleus, Alzheimer's disease, reversal learning, tau hyperphosphorylation, noradrenergic dysfunction, norepinephrine, TgF344-AD rats, medial entorhinal cortex, DREADD, chemogenetic activation, mild cognitive impairment, preclinical models
- MeSH terms
- Alzheimer Disease, Animals, Cells, Cultured, Disease Models, Animal, Female, Locus Coeruleus, Male, Rats, Inbred F344, Reversal Learning, tau Proteins, Maze Learning, Rats, Rats, Transgenic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.